ABio-X

2023年5月2日

Adcentrx療法——一個生物科技公司致力於革新抗體藥物共軛(ADC)療法對癌症和其他危及生命的疾病——宣布關閉係列+融資3800萬美元。一輪融資是由八公路企業參與,從f '資本ABio-X,δ資本,三位一體創新基金和其他戰略投資者。生活Venture Partners和燈塔資本充當Adcentrx的金融顧問。Adcentrx計劃通過融資所得來推進其專有的ADC治療管道到診所。adc的被稱為一個類療法結合的目標特異性抗體與傳統化療藥物的效力。這類腫瘤的治療發生了革命性變化景觀與潛在的積極影響其他嚴重疾病。Adcentrx區分本身利用團隊的行業領先的ADC藥物開發經驗以及深刻的化學和生物學方麵的專長。和團隊的發展開創了ADC技術工具箱解決關鍵組件的蛋白質結合設計解決的挑戰出現在前幾代的ADC。Adcentrx實現這種優化方法,燃料的開發一個健壯的管道first-in-class和最佳的治療方法。和公司的領先候選人adrx - 0706預計進入first-in-human 1期臨床試驗在2023年下半年。 Plus Adcentrx is developing additional candidates in parallel with the goal of advancing at least one into the clinic each year. KEY QUOTES: “We are thrilled to have Eight Roads and our investors supporting our mission to bring innovative treatments to patients. Over the last two years, we have made significant progress advancing our emerging therapeutic pipeline that implements our proprietary and differentiated technology platform. This new round of funding from our investors will enable Adcentrx to quickly advance our safer and more efficacious conjugate therapies for patients in need. This year will be pivotal for Adcentrx, when we transition from the discovery stage into a clinical-stage company.” Hui Li, Ph.D., Founder and CEO of Adcentrx “ADCs as a therapeutic modality have flourished in recent years with a transformative inflow of active investment and strategic transactions. Adcentrx has demonstrated good potential of developing differentiated ADCs for unmet medical needs. We are very excited to lead this round of financing to empower Adcentrx to accelerate its work in bringing new hope to patients in need.” Tao Huang, Ph.D., Principal of Eight Roads Ventures “Through its innovative work in the ADC field, Adcentrx exemplifies the type of company that ABio-X was designed to support as a global platform for developing the next generation healthcare companies. We are pleased to join together with other quality investors in this financing round and look forward to continuing our support of Adcentrx through the platform and board representation.” Jeff Jonas, President and CEO of ABio-X “Adcentrx has made significant progress in building its preclinical pipeline and platform technology since our initial investment. Together with our ABio-X colleagues, we are pleased to reaffirm our commitment to support the company’s continued growth and development.” Meng Jiang, Head, Venture Capital at CBC Group “As an innovation company with a global vision, Adcentrx leverages its technology platform to address the challenges of ADC drug development. It is a privilege to participate in this round of financing that attracted investment from renowned funds and industry players, indicating the company’s growing prominence within the industry. We look forward to Adcentrx’s continued progress of advancing its novel ADCs into the clinic.” Lei Hong, Executive Director of Lighthouse Capital Trending on Pulse 2.0